BioLineRx Net Worth
BioLineRx Net Worth Breakdown | BLRX |
BioLineRx Net Worth Analysis
BioLineRx's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioLineRx's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioLineRx's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioLineRx's net worth analysis. One common approach is to calculate BioLineRx's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioLineRx's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioLineRx's net worth. This approach calculates the present value of BioLineRx's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioLineRx's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioLineRx's net worth. This involves comparing BioLineRx's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioLineRx's net worth relative to its peers.
Enterprise Value |
|
To determine if BioLineRx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioLineRx's net worth research are outlined below:
| BioLineRx generated a negative expected return over the last 90 days | |
| BioLineRx has high historical volatility and very poor performance | |
| BioLineRx has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.8 M. Net Loss for the year was (60.61 M) with profit before overhead, payroll, taxes, and interest of 15.12 M. | |
| BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| BioLineRx has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: BLRX Aphexda Transition Progressing |
BioLineRx Quarterly Good Will |
|
BioLineRx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioLineRx. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioLineRx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 22nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
BioLineRx Target Price Consensus
BioLineRx target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. BioLineRx's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most BioLineRx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand BioLineRx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of BioLineRx, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBioLineRx Target Price Projection
BioLineRx's current and average target prices are 3.00 and 4.57, respectively. The current price of BioLineRx is the price at which BioLineRx is currently trading. On the other hand, BioLineRx's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On BioLineRx Target Price
Know BioLineRx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioLineRx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLineRx backward and forwards among themselves. BioLineRx's institutional investor refers to the entity that pools money to purchase BioLineRx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Envestnet Asset Management Inc | 2024-12-31 | 0.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Wells Fargo & Co | 2024-12-31 | 0.0 | |
| Cutter & Co Brokerage, Inc. | 2024-12-31 | 0.0 | |
| Atria Wealth Solutions, Inc. | 2024-12-31 | 0.0 | |
| Rathbone Brothers Plc | 2024-12-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | |
| Atria Investments Llc | 2024-12-31 | 0.0 | |
| Virtu Financial Llc | 2024-12-31 | 0.0 | |
| Values First Advisors Inc | 2024-12-31 | 166.4 K | |
| Rhumbline Advisers | 2024-12-31 | 43 K |
Follow BioLineRx's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.24 M.Market Cap |
|
Project BioLineRx's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.42) | (1.49) | |
| Return On Capital Employed | (1.35) | (1.28) | |
| Return On Assets | (0.85) | (0.81) | |
| Return On Equity | (5.27) | (5.01) |
When accessing BioLineRx's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioLineRx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioLineRx's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioLineRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLineRx. Check BioLineRx's Beneish M Score to see the likelihood of BioLineRx's management manipulating its earnings.
Evaluate BioLineRx's management efficiency
BioLineRx has return on total asset (ROA) of (0.3296) % which means that it has lost $0.3296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8409) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.49 in 2025. Return On Capital Employed is likely to rise to -1.28 in 2025. Debt To Assets is likely to rise to 0.17 in 2025, whereas Total Assets are likely to drop slightly above 53.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | (1.76) | (1.85) | |
| Price Book Value Ratio | 7.09 | 7.44 | |
| Enterprise Value Multiple | (1.76) | (1.85) | |
| Price Fair Value | 7.09 | 7.44 | |
| Enterprise Value | 100.4 M | 105.4 M |
The strategic initiatives led by BioLineRx's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
BioLineRx Corporate Filings
6K | 21st of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 10th of January 2025 Other Reports | ViewVerify | |
| 7th of January 2025 Other Reports | ViewVerify | |
| 27th of December 2024 Other Reports | ViewVerify |
BioLineRx Earnings Estimation Breakdown
The calculation of BioLineRx's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioLineRx is estimated to be -0.8 with the future projection ranging from a low of -0.8 to a high of -0.8. Please be aware that this consensus of annual earnings estimates for BioLineRx is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.8 Lowest | Expected EPS | -0.8 Highest |
BioLineRx Earnings Projection Consensus
Suppose the current estimates of BioLineRx's value are higher than the current market price of the BioLineRx stock. In this case, investors may conclude that BioLineRx is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BioLineRx's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 2 | 56.09% | -0.0728 | -0.8 | -12.0 |
BioLineRx Earnings per Share Projection vs Actual
Actual Earning per Share of BioLineRx refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering BioLineRx predict the company's earnings will be in the future. The higher the earnings per share of BioLineRx, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.BioLineRx Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as BioLineRx, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of BioLineRx should always be considered in relation to other companies to make a more educated investment decision.BioLineRx Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact BioLineRx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.1 | -0.0728 | 0.0272 | 27 | ||
2024-08-15 | 2024-06-30 | -0.14 | 0.0061 | 0.1461 | 104 | ||
2024-05-28 | 2024-03-31 | -0.29 | -0.01 | 0.28 | 96 | ||
2024-03-28 | 2023-12-31 | -0.16 | -0.15 | 0.01 | 6 | ||
2023-11-20 | 2023-09-30 | -0.21 | -0.01 | 0.2 | 95 | ||
2023-08-30 | 2023-06-30 | -0.11 | -0.3 | -0.19 | 172 | ||
2023-05-25 | 2023-03-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2023-03-22 | 2022-12-31 | -0.135 | -0.09 | 0.045 | 33 | ||
2022-11-15 | 2022-09-30 | -0.16 | -0.01 | 0.15 | 93 | ||
2022-09-30 | 2022-06-30 | -0.11 | -0.15 | -0.04 | 36 | ||
2022-05-25 | 2022-03-31 | -0.09 | -0.15 | -0.06 | 66 | ||
2022-03-16 | 2021-12-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2021-12-09 | 2021-09-30 | -0.16 | -0.15 | 0.01 | 6 | ||
2021-08-18 | 2021-06-30 | -0.15 | -0.15 | 0.0 | 0 | ||
2021-05-26 | 2021-03-31 | -0.15 | -0.3 | -0.15 | 100 | ||
2021-02-23 | 2020-12-31 | -0.28 | -0.6 | -0.32 | 114 | ||
2020-11-23 | 2020-09-30 | -0.35 | -0.3 | 0.05 | 14 | ||
2020-08-06 | 2020-06-30 | -0.73 | -0.45 | 0.28 | 38 | ||
2020-05-20 | 2020-03-31 | -0.82 | -0.6 | 0.22 | 26 | ||
2020-03-12 | 2019-12-31 | -0.66 | -0.9 | -0.24 | 36 | ||
2019-11-19 | 2019-09-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2019-08-06 | 2019-06-30 | -0.63 | -0.6 | 0.03 | 4 | ||
2019-05-14 | 2019-03-31 | -0.75 | -0.75 | 0.0 | 0 | ||
2019-03-28 | 2018-12-31 | -1.39 | -0.6 | 0.79 | 56 | ||
2018-11-08 | 2018-09-30 | -0.82 | -0.9 | -0.08 | 9 | ||
2018-08-13 | 2018-06-30 | -0.9 | -0.75 | 0.15 | 16 | ||
2018-05-22 | 2018-03-31 | -1.05 | -0.9 | 0.15 | 14 | ||
2018-03-06 | 2017-12-31 | -0.94 | -1.2 | -0.26 | 27 | ||
2017-11-21 | 2017-09-30 | -0.82 | -1.05 | -0.23 | 28 | ||
2017-08-08 | 2017-06-30 | -0.82 | -0.75 | 0.07 | 8 | ||
2017-05-25 | 2017-03-31 | -0.85 | -1.2 | -0.35 | 41 | ||
2017-03-23 | 2016-12-31 | -1.2 | -1.05 | 0.15 | 12 | ||
2016-11-22 | 2016-09-30 | -1.1 | -1.2 | -0.1 | 9 | ||
2016-08-11 | 2016-06-30 | -1.1 | -1.05 | 0.05 | 4 | ||
2016-05-17 | 2016-03-31 | -1.15 | -0.96 | 0.19 | 16 | ||
2016-03-10 | 2015-12-31 | -0.9 | -1.05 | -0.15 | 16 | ||
2015-11-16 | 2015-09-30 | -1.25 | -0.45 | 0.8 | 64 | ||
2015-08-20 | 2015-06-30 | -1.12 | -1.35 | -0.23 | 20 | ||
2015-05-18 | 2015-03-31 | -0.9 | -1.5 | -0.6 | 66 | ||
2015-03-23 | 2014-12-31 | -3.6 | -0.13 | 3.47 | 96 | ||
2014-11-10 | 2014-09-30 | -2.47 | -0.3 | 2.17 | 87 | ||
2014-08-06 | 2014-06-30 | -1.65 | -1.8 | -0.15 | 9 | ||
2014-05-20 | 2014-03-31 | -1.57 | -1.5 | 0.07 | 4 | ||
2014-03-17 | 2013-12-31 | -2.25 | -3.0 | -0.75 | 33 | ||
2013-11-13 | 2013-09-30 | -2.62 | -3.0 | -0.38 | 14 | ||
2013-08-06 | 2013-06-30 | -1.65 | -2.85 | -1.2 | 72 | ||
2013-05-07 | 2013-03-31 | -1.95 | -0.3 | 1.65 | 84 | ||
2013-03-12 | 2012-12-31 | -4.2 | -4.5 | -0.3 | 7 | ||
2012-11-14 | 2012-09-30 | -3.45 | -6.0 | -2.55 | 73 | ||
2012-08-15 | 2012-06-30 | -3.75 | -2.4 | 1.35 | 36 |
BioLineRx Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Raziel Fried | Treasurer Director | Profile | |
| Adam Esq | General Compliance | Profile | |
| Jael MSc | QA RA | Profile | |
| CPA MBA | Chief Officer | Profile |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.